We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.50 | 0.98% | 1,599.00 | 1,599.50 | 1,600.50 | 1,600.00 | 1,575.00 | 1,579.50 | 5,149,016 | 16:35:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.37 | 65.87B |
Date | Subject | Author | Discuss |
---|---|---|---|
16/11/2017 10:01 | The market for this is huge - COPD is a progressive lung disease that is thought to affect around 384 million people worldwide. | tradermichael | |
16/11/2017 09:25 | when will we go sub £13 | billionaire1 | |
16/11/2017 09:24 | Trelegy looks a great products, the question atm is not around its efficacy, it's the price positioning and whether it can build decent share. | essentialinvestor | |
16/11/2017 09:20 | Another good RNS. | spcecks | |
16/11/2017 09:10 | ...... and the dividend becomes more affordable. The last two are blockbusters. | tradermichael | |
16/11/2017 09:01 | ......and the share price continues to fall. | bili1946 | |
16/11/2017 07:55 | Excellent product news accelerates ...... ;0) | tradermichael | |
16/11/2017 07:53 | Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe. It is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA), delivered once daily in GSK's Ellipta dry powder inhaler. | tradermichael | |
15/11/2017 17:10 | I have too many of these so keep saying enough is enough, but then the price falls so I buy more. Bought again today at 1309. I cannot really believe it. | jadeticl3 | |
15/11/2017 16:41 | Pipeline better focused now than it was when it was at £17+ | romeike | |
15/11/2017 13:54 | Yes guys but it's surely fair value now? | mj19 | |
15/11/2017 13:39 | Monty, it's the pipeline as well imv. That oncology compound needs to continue to advance through trials. | essentialinvestor | |
15/11/2017 13:37 | MJShould also opened her big mouth about possible bid for Pfizer heath div.Hope she does not player poker, she would show her cards. Naive. | montyhedge | |
15/11/2017 13:36 | Woodhawk - "Decided to add some more myself - averaging down from £13.60. Crazy" Depends on your time scale, lot of people on here count in days or maybe weeks, but some are long term and look to next year or even (as the institutions are always saying) five years. Good luck with your purchase. | losos | |
15/11/2017 13:36 | You know is what the old City saying is ... Everyone is a genius in a bull market! ). A tad tougher when markets begin to turn. | essentialinvestor | |
15/11/2017 13:29 | woodhawk - "My entire portfolio has doubled in less than three years through capital gains and reinvested dividends." Well you've done better than me, mind you that's not difficult haha. | losos | |
15/11/2017 12:33 | Looks like it may want sub £13, let's see | essentialinvestor | |
15/11/2017 12:12 | This is a strong buyMs Walmsley warned GSK was "moving forward with contingency planning right now" and would start spending within weeks on drawing up plans for duplicate medicine testing centres in the EU and preparing for separate drug licensing regimes both of which would be needed in the event of a so-called "hard Brexit".GSK wants Brexit transition arrangements of "at least two years", Ms Walmsley said. She said she did not expect the Brexit-related costs to be material to its results. | mj19 | |
15/11/2017 12:08 | Yes but shorters are never satisfied! | abdullla | |
15/11/2017 10:18 | Surely everything for now is priced in? | mj19 | |
15/11/2017 10:17 | Decided to add some more myself - averaging down from £13.60. Crazy. | woodhawk | |
15/11/2017 10:14 | So we have resistance at 1324 and support at 1310 for now | mj19 | |
15/11/2017 10:01 | Nice buying NY Boy. | woodhawk | |
15/11/2017 09:57 | Ignore the noise, added more this morning, I love a bargain to tuck away and happy to collecting quarterly divis 6.08% per ammun thank you very much! Gift of the year | ny boy | |
15/11/2017 08:23 | Thanks TM,got them but sadly sitting on a loss,waiting for a blessing in disguise and divi! | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions